ClinicalTrials.gg
RecruitingNCT06991517Updated Jul 21, 2026

A Study of Transcatheter Aortic Valve Replacement Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm

An observational study in Aortic Stenosis, sponsored by World Health Research Inc.. Recruiting at 20 sites in 8 countries. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by World Health Research Inc. · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
290
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Aortic Valve Stenosis with a site in Canada — 23 open to participants now, 36 under way, 1 of them phase 3. Aortic Valve Stenosis · Canada.

Planned enrollment
15th of 27
290 · median 320
Started
2025
with 2 others
Observational
27 of 87
8 open now
Primary completion
2026-12
later than 16 of 35 live
Registered
84th of 87
by date

Among the 87 studies in Aortic Valve Stenosis with a site in Canada, this one is the 15th largest by planned enrollment of the 27 observational ones that give a count, is one of 3 that started in 2025, is one of 27 observational ones, reaches primary completion later than 16 of the 35 other live ones, and was the 84th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

23 of the 87 studies in Aortic Valve Stenosis with a site in Canada are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Aortic Valve Stenosis with a site in Canada, or all of them as a file.
02

Study summary

The goal of this study is to learn what effects the ABC Bicuspid Sizing Algorithm has on the clinical outcomes of patients with bicuspid aortic stenosis after having a transcatheter aortic valve replacement (TAVR) using the Sapien 3 valve. The main questions the study aims to answer are:

  1. Does the ABC Bicuspid Sizing Algorithm increase the technical success at exit from the procedure room?
  2. Does the ABC Bicuspid Sizing Algorithm increase the device success at 30 days after the procedure?

Participants already being evaluated for a TAVR as part of their regular medical care for bicuspid aortic stenosis will have their diagnostic images assessed using the ABC Bicuspid Sizing Algorithm to help determine their procedure type and valve size. They will have visits 30 days and annually till 5 years after their procedure.

Read the detailed description

This is a multi-centre, international, prospective cohort study. Approximately 290 patients who are clinically eligible for transcatheter aortic valve replacement (TAVR) will be enrolled. Using information collected with the ABC Bicuspid Sizing Algorithm, physicians will make a treatment allocation between TAVR and surgical aortic valve replacement (SAVR), and determine valve sizing and deployment for TAVR-treated patients. Included in the algorithm use is the utilization of gated computed tomography evaluation or artificial intelligence-based simulation models in select cases with borderline feasibility. The findings of these additional assessments will be shared with the treating physicians for consideration in the final treatment decision.

Of the 290 patients, an estimated 230 will be recommended to have TAVR. Data will be collected from TAVR-treated patients at baseline, procedure, hospital discharge, and 30 days and annually till 5 years after the procedure. Data will only be collected from SAVR-treated patients at baseline and procedure. Sites in Canada, Latin America, the Middle East, and Asia Pacific will participate.

03

Conditions studied

  • Aortic Stenosis

Keywords

  • Bicuspid Aortic Stenosis
  • Transcatheter Aortic Valve Replacement
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients referred to the TAVR program at select hospitals

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have bicuspid aortic valve disease
  • Have severe aortic stenosis or mixed aortic stenosis and regurgitation requiring treatment
  • Have no other condition requiring surgical intervention
  • Have had a TAVR CT scan (retrospectively gated contrast enhanced acquisition) that is of diagnostic quality and includes multiphase reconstructions of the aortic root at the minimum available slice thickness (with at least three systolic and one diastolic phases)
  • Would be treated with a Sapien 3 valve if found to be anatomically suitable for TAVR
  • Have a suitable access route for TAVR with a Sapien 3 valve

Exclusion criteria

Exclusion Criteria:

  • Are treated with TAVR using a device other than a Sapien 3 valve
  • Are unable to be treated with TAVR due to intercurrent illness, clinical instability, or death on waitlist after being accepted for TAVR
  • TAVR considered high risk and not feasible due to risk of coronary occlusion, risk of sino tubular junction (STJ) injury and severe LVOT calcification
  • Annular area less than 275 mm² or more than 750 mm²
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
290 participants (estimated)
Patient registry
No

Interventions

  • OtherThe ABC Bicuspid Sizing Algorithm

    The ABC Bicuspid Sizing Algorithm is a valve sizing algorithm. It guides operators' evaluations of CT scans, helping inform (1) treatment allocation between TAVR and surgical aortic valve replacement, and (2) valve choice for patients undergoing TAVR. In select cases, the algorithm will suggest gated CT evaluation or artificial intelligence-based simulation models be used to further evaluate the risk of the planned valve size and deployment volume. The operators will consider the findings of the ABC Bicuspid Sizing Algorithm as well as other clinical factors when making their final treatment decisions.

06

What researchers measure

Primary outcomes

  1. Proportion of cases achieving technical success

    Freedom from mortality, successful access, delivery of the device, and retrieval of the delivery system, correct positioning of a single prosthetic heart valve into the proper anatomical location, and freedom from surgery or intervention related to the device or cardiac structural complication

    Time frame: At exit from procedure room after procedure completion

Secondary outcomes

  1. Proportion of cases achieving device success

    Technical success and intended performance of the valve (mean gradient less than 20 mmHg, peak velocity less than 3 m/s, Doppler velocity index greater than 0.35, and less than moderate aortic regurgitation)

    Time frame: At 30 days after the procedure

  2. Proportion of cases in which the use of gated computed tomography evaluation or artificial intelligence-based simulation models altered the treatment plan or operator confidence in the treatment plan compared to the ABC Bicuspid Sizing Algorithm alone

    Time frame: At baseline

  3. New conduction disturbance and permanent pacemaker implantation

    Time frame: At 30 days and 1,3 and 5 years after the procedure

  4. Stroke or transient ischemic attack

    Time frame: At 30 days and 1,3 and 5 years after the procedure

  5. Major vascular complication

    Time frame: At 30 days after the procedure

  6. Death

    Time frame: At 30 days and 1,3 and 5 years after the procedure

  7. Acute valve complication

    Time frame: Perioperative/Periprocedural

  8. Need for cardiac surgery

    Time frame: At 30 days and 1,3 and 5 years after the procedure

  9. Delayed valve dysfunction

    Time frame: At 30 days ,1,3 and 5 years after the procedure

  10. Proportion of cases in which evaluation of anatomy above or below the annulus altered the valve sizing and deployment decision compared to the calculated valve sizing and deployment decision considering the annulus size only

    Time frame: At baseline

  11. Hospitalization for acute heart failure

    Time frame: 1,3 and 5 years after the procedure

07

Study locations

17 of 20 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 37 industry-sponsored observational studies under Aortic Valve Stenosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 19 months is below that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
May 28, 2025
StartActual
May 13, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2031
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06991517
Lead sponsor
World Health Research Inc.
Responsible party
Sponsor
First posted
May 28, 2025
Start date
May 13, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2031 (estimated)
Last update
Jul 21, 2026

Study contacts

Sarah Tawadros, MD
Contact
sarah.tawadros@worldhealthresearch.ca
647-783-3521
Frank Naus
Contact
frank.naus@worldhealthresearch.ca
416-706-2579
Tej PM Sheth, MD, FRCPC
principal investigator · McMaster University, World Health Research Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion